Donoghue Forlines LLC Purchases Shares of 4,627 Alnylam Pharmaceuticals, Inc. $ALNY

Donoghue Forlines LLC purchased a new stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) during the third quarter, Holdings Channel reports. The firm purchased 4,627 shares of the biopharmaceutical company’s stock, valued at approximately $2,110,000.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Vanguard Group Inc. lifted its position in Alnylam Pharmaceuticals by 1.8% during the second quarter. Vanguard Group Inc. now owns 13,297,139 shares of the biopharmaceutical company’s stock valued at $4,336,064,000 after acquiring an additional 240,534 shares during the last quarter. Geode Capital Management LLC increased its position in shares of Alnylam Pharmaceuticals by 3.3% during the second quarter. Geode Capital Management LLC now owns 2,398,770 shares of the biopharmaceutical company’s stock worth $779,857,000 after purchasing an additional 75,936 shares in the last quarter. Orbis Allan Gray Ltd lifted its holdings in shares of Alnylam Pharmaceuticals by 29.8% during the 2nd quarter. Orbis Allan Gray Ltd now owns 2,121,412 shares of the biopharmaceutical company’s stock valued at $691,771,000 after purchasing an additional 486,489 shares during the last quarter. Norges Bank acquired a new stake in shares of Alnylam Pharmaceuticals in the 2nd quarter worth $662,837,000. Finally, American Century Companies Inc. grew its stake in Alnylam Pharmaceuticals by 1.9% during the 2nd quarter. American Century Companies Inc. now owns 1,793,846 shares of the biopharmaceutical company’s stock worth $584,957,000 after buying an additional 33,411 shares during the last quarter. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Insider Transactions at Alnylam Pharmaceuticals

In other news, EVP Tolga Tanguler sold 1,510 shares of the business’s stock in a transaction that occurred on Monday, January 12th. The stock was sold at an average price of $362.87, for a total value of $547,933.70. Following the completion of the sale, the executive vice president directly owned 29,728 shares in the company, valued at $10,787,399.36. The trade was a 4.83% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Kevin Joseph Fitzgerald sold 12,128 shares of the company’s stock in a transaction that occurred on Monday, November 17th. The stock was sold at an average price of $452.18, for a total value of $5,484,039.04. Following the transaction, the executive vice president directly owned 21,264 shares of the company’s stock, valued at approximately $9,615,155.52. The trade was a 36.32% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 56,955 shares of company stock worth $24,072,733 over the last quarter. Company insiders own 1.50% of the company’s stock.

Wall Street Analyst Weigh In

ALNY has been the subject of a number of research analyst reports. Piper Sandler reiterated an “overweight” rating and issued a $489.00 price target (up from $449.00) on shares of Alnylam Pharmaceuticals in a research note on Friday, October 31st. Wall Street Zen upgraded shares of Alnylam Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Monday, November 10th. HC Wainwright set a $570.00 target price on shares of Alnylam Pharmaceuticals and gave the stock a “buy” rating in a research note on Tuesday, November 4th. Stifel Nicolaus boosted their target price on shares of Alnylam Pharmaceuticals from $495.00 to $508.00 and gave the stock a “buy” rating in a research report on Thursday, December 11th. Finally, Jefferies Financial Group decreased their price target on shares of Alnylam Pharmaceuticals from $550.00 to $549.00 and set a “buy” rating for the company in a report on Thursday, October 30th. Twenty-two analysts have rated the stock with a Buy rating and five have given a Hold rating to the company. According to MarketBeat.com, Alnylam Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $490.96.

Alnylam Pharmaceuticals Stock Up 0.0%

ALNY stock opened at $359.27 on Friday. The firm’s fifty day moving average is $418.74 and its 200 day moving average is $422.05. The firm has a market cap of $47.46 billion, a PE ratio of 1,496.96 and a beta of 0.32. Alnylam Pharmaceuticals, Inc. has a one year low of $205.87 and a one year high of $495.55. The company has a debt-to-equity ratio of 4.45, a quick ratio of 2.49 and a current ratio of 2.54.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.